RT Generic
T1 Statins in Non-alcoholic Steatohepatitis
A1 Torres-Pena, Jose D.
A1 Martin-Piedra, Laura
A1 Fuentes-Jimenez, Francisco
K1 statins
K1 NASH
K1 cardiovascular disease
K1 liver
K1 aminotransferase
K1 Fatty liver-disease
K1 Coronary-heart-disease
K1 Crown-like structures
K1 Metabolic syndrome
K1 Cardiovascular events
K1 Cholesterol crystals
K1 Greek atorvastatin
K1 Genetic-factors
K1 Safety
K1 Nash
AB Non-alcoholic fatty liver disease (NAFLD) is the primary cause of chronic liver disease. The range is extensive, including hepatocellular carcinoma, cirrhosis, fibrosis, fatty liver, and non-alcoholic steatohepatitis (NASH). NASH is a condition related to obesity, overweight, metabolic syndrome, diabetes, and dyslipidemia. It is a dynamic condition that can regress to isolated steatosis or progress to fibrosis and cirrhosis. Statins exert anti-inflammatory, proapoptotic, and antifibrotic effects. It has been proposed that these drugs could have a relevant role in NASH. In this review, we provide an overview of current evidence, from mechanisms of statins involved in the modulation of NASH to human trials about the use of statins to treat or attenuate NASH.
PB Frontiers media sa
SN 2297-055X
YR 2021
FD 2021-11-24
LK https://hdl.handle.net/10668/25859
UL https://hdl.handle.net/10668/25859
LA en
DS RISalud
RD Apr 18, 2025